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Volume 52, Number 4 Abstracts 1123identity are plastic, and changes are found similar to those previously
reported in human vein graft adaptation and animal models. These bioreac-
tors adequately mimic the human arterial environment and enable testing of
potential therapeutic agents directed against neointimal hyperplasia.
CTGF is a Marker of Promigratory Subpopulation of Human Vascular
Smooth Muscle Cells: Target for Treatment of Intimal Hyperplasia
Robert Wagner1, Amber Liu2, Richard Powell1, Eva M. Rzucidlo1
1Dartmouth-Hitchcock Medical Center, Lebanon, NH; 2Dartmouth Med-
ical School, Hanover, NH
Introduction and objectives: Understanding the processes that con-
trol vascular smooth muscle cell (VSMC) phenotypic modulation and
determining which subpopulation of VSMCs migrate is critical for the
design of treatment of intimal hyperplasia. Connective tissue growth factor
(CTGF) has recently been reported to be upregulated in a variety of fibrotic
disorders. We hypothesize that CTGF is a marker of a dedifferentiated
VSMCs and therefore a target for treatment of intimal hyperplasia.
Methods: Western blot analysis was used to determine protein expres-
sion. Bowden chambers were used for VSMC migration. Magnetic beads
were labeled with CTGF antibody according to the manufacture’s protocol.
Porcine carotid arteries were microdissected into inner layer (intima/media)
and outer layer (media/adventitia). VSMCs were transfected with myr-
AKT1 using the nucleofection technique. Pig iliac arteries were injured and
organ-cultured for 7 days.
Results: Intimal hyperplastic VSMCs had higher baseline CTGF ex-
pression than normal VSMCs. VSMCs in the inner intimal/medial layer had
increased differentiation markers. Outer medial/adventitial layer VSMCs
had decreased contractile protein expression and increased CTGF expres-
sion. Balloon injury led to increased expression of CTGF in a subpopulation
of VSMC as well as CTGF expression in cells within the intimal hyperplastic
lesion. Intimal hyperplasia was recapitulated by addition of exogenous
CTGF. High-expressing CTGF VSMCs (magnetic bead isolated) had de-
creased contractile protein expression and increased extracellular matrix
expression. CTGF-positive VSMCs had 60% increased migration. Exoge-
nous CTGF increased VSMC migration in a dose-dependent manner.
Overexpression of myr-AKT1 increased CTGF and collagen IV expression
in VSMCs.
Conclusions:CTGF is an important regulator of VSMC migration and
vascular remodeling through AKT1. CTGF is overexpressed in a subpopu-
lation of VSMCs, which may be the promigratory cells that populate intimal
hyperplasia lesions. These data will allow for more targeted therapies for
intimal hyperplasia.
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Introduction and objectives: This study evaluated the impact of
balloon-expandable Palmaz stents for treatment of type I endoleaks during
EVAR.
Methods: During an 8-year period, 1378 patients underwent EVAR
using commercially available stent grafts. Patients were categorized into two
groups: (1) adjunctive use of the Palmaz stent for treatment of type I
endoleak during EVAR (EVAR  Palmaz stent: n  146, 11%) and (2)
EVAR without Palmaz stent (EVAR only: n  1232, 89%). Patient fol-
low-up included CTA and duplex ultrasound imaging at 1 and 6 months,
and every 12 months thereafter. Data were prospectively collected in a
vascular registry, and all variables were analyzed.
Results: Of the 1378 patients, the EVAR  Palmaz stent group (n 
146, 11%) had a significantly higher incidence of ischemic colitis (6.9% vs
0.7%, P .05), persistent or new type I endoleaks (13% vs 7%, P .05), type
II endoleaks (32% vs 23%, P  .05), and secondary interventions (31% vs.
19%, P .05). A significantly higher percentage of women required Palmaz
stents during EVAR (17% vs 8%, P .05). The EVAR Palmaz stent group
also had a higher 30-day mortality (3.4% vs 1.4%) and a higher incidence ofstent graft explant (2.7% vs 0.97%), although this difference did not reach
statistical significance (Table).
Conclusions: The adjunctive use of balloon-expandable Palmaz stents
during EVAR is not a benign procedure and increases the risks for develop-
ing ischemic colitis, recurrent type I and type II endoleaks, and requiring
secondary interventions. Furthermore, women have nearly a twofold in-
creased risk or requiring a Palmaz stent during EVAR.
Table. Outcomes of EVAR with and without Palmaz
stent
Variable
EVAR  Palmaz
stent EVAR only P
No. (%) No. (%)
Number 146 (11) 1232 (89)
Female 56 (38) 263 (21) .05
Ischemic colitis 10 (6.9) 19(0.7) .05
Type I endoleak 19 (13) 87(7) .05
Type II endoleak 46 (32) 283(23) .05
Secondary interventions 45 (31) 228(19) .05
Stent graft explant 4 (2.7) 12 (0.97) .12
30-day mortality 5 (3.4) 17(1.4) .17
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Introduction:Bone marrow is rich in progenitor and other supporting
cells. We conducted a pilot study using bone marrow aspirate concentrate
(BMAC) to treat critical limb ischemia (CLI).
Methods: A prospective, randomized, double-blinded, placebo-con-
trolled pilot study was conducted at eight centers. Patients with critical climb
ischemia (ABI0.4, TBI0.4, or TcPO220), Rutherford clinical class 4
or 5, who were poor candidates for conventional revascularization were
enrolled with 2 (BMAC):1 (control) randomization. BMAC patients under-
went a 240-mL aspiration. The control group underwent a bilateral 1-mL
aspiration. Bone marrow was concentrated in the operating room using an
automated, decanting centrifuge. The placebo injectate was created from
peripheral blood. The blinded treatment team injected the material into the
extremity in a series of 40 1-mL injections.
Results: A total of 48 patients were treated using conscious sedation
between November 2007 and October 2009, comprising 32 men (67%);
mean age, 69 (range, 42-93). At the 12-week follow-up, there were no
deaths and nine major limb amputations: four (28.6%) in controls and five
(14.7%) in BMAC. Adverse events were reported in 74% of BMAC and 64%
of controls, none related to the study treatment. ABIs were unchanged in
controls but increased by 0.1 in BMAC patients (P .01). Pain assessed on
a 100-mm scale improved (decreased 30 mm) in 11 of 25 BMAC (44%)
and in 2 of 8 controls (25%). We developed a composite index: patients were
“improved” if they survived without a major amputation and their Ruther-
ford clinical class and/or pain decreased. Composite improvement was
noted in 16 of 31 BMAC (52%) vs 3 of 13 controls (23%; P  .1).
Conclusions: BMAC holds great promise for the treatment of CLI.
Our composite index incorporates the major relevant determinants of suc-
cess in advanced CLI, with BMAC patients achieving twice the success of
controls. A robust pivotal trial is needed to verify and expand on these
preliminary results.
